Tirzepatide for Weight Loss

Tirzepatide is a GLP-1/GIP receptor agonist that has been evaluated in FDA-approved medications such as Mounjaro®. It acts on two naturally occurring hormones involved in appetite signaling and blood-sugar regulation. Nexlife may offer compounded tirzepatide, prepared by licensed compounding pharmacies, when a provider determines that FDA-approved options are unavailable or not clinically appropriate. Compounded tirzepatide is not FDA-approved.

Tirzepatide works by affecting hormones involved in appetite and glucose regulation. Clinical trials of FDA-approved tirzepatide have shown meaningful weight loss outcomes in some participants when combined with diet and lifestyle changes.

Eligibility is determined by a licensed provider following a medical consultation. Clinical guidelines for FDA-approved GLP-1/GIP therapies generally include adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions such as type 2 diabetes or high blood pressure. Providers assess each patient individually to decide whether compounded tirzepatide is an appropriate option.

Nexlife connects patients with U.S.-licensed providers who review treatment options and decide if compounded GLP-1/GIP medications are clinically appropriate. Prescriptions, when issued, are dispensed through licensed compounding pharmacies that may use independent third-party testing for quality. Medications are delivered directly to patients with clear pricing and continued provider support. Note: Compounded medications are not FDA-approved.